Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival

Molecular Pharmacology

Volumn 68, Issue 6, 2005, Pages 1636-1644

  Karnitz, Larry M ^a,c   Flatten, Karen S ^a   Wagner, Jill M ^a   Loegering, David ^a   Hackbarth, Jennifer S ^a   Arlander, Sonnet J H ^a   Vroman, Benjamin T ^a   Thomas, M Bijoy ^a   Baek, Yong Un ^a   Hopkins, Kevin M ^b   Lieberman, Howard B ^b   Chen, Junjie ^a   Cliby, William A ^a   Kaufmann, Scott H ^a  

^a MAYO CLINIC   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYTARABINE; GEMCITABINE; PROTEIN KINASE; PROTEIN P53; PROTEIN RAD1; PROTEIN RAD9;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; SENSITIZATION; SIGNAL TRANSDUCTION; TUMOR CELL;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CYTARABINE; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 27844561114     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.012716.     Document Type: Article

References (40)

1. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, and Karnitz LM (2003) Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 278:52572-52577.
2. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley JN, Ried T, Tagle D, et al. (1996) ATM-deficient mice: a paradigm of ataxia telangiectasia. Cell 86:159-171.
3. Bermudez VP, Lindsey-Boltz LA, Cesare AJ, Maniwa Y, Griffith JD, Hurwitz J, and Sancar A (2003) Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro. Proc Natl Acad Sci USA 100:1633-1638.
4. Bianchi V, Pontis E, and Reichard P (1986) Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem 261:16037-16042.
5. Bolderson E, Scorah J, Helleday T, Smythe C, and Meuth M (2004) ATM is required for the cellular response to thymidine induced replication fork stress. Hum Mol Genet 13:2937-2945.
6. Boultwood J (2001) Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J Clin Pathol 54:512-516.
7. Brown EJ and Baltimore D (2000) ATR disruption leads to chromosomal fragmentation and early embryonic death. Genes Dev 14:397-402.
8. Burma S, Chen BP, Murphy M, Kurimasa A, and Chen DJ (2001) ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 276:42462-42467.
9. Burtelow MA, Kaufmann SH, and Karnitz LM (2000) Retention of the hRad9 checkpoint complex in extraction-resistant nuclear complexes after DNA damage. J Biol Chem 275:26343-26348.
10. Busino L, Chiesa M, Draetta GF, and Donzelli M (2004) Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 23:2050-2056.
11. Carmichael J (1998) The role of gemcitabine in the treatment of other tumours. Br J Cancer 78 (Suppl 3):21-25.
12. Casper AM, Nghiem P, Arlt MF, and Glover TW (2002) ATR regulates fragile site stability. Cell 111:779-789.
13. Cho SH, Toouli CD, Fujii GH, Crain C, and Parry D (2005) Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 4:131-139.
14. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL, and Friend SH (1998) Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO (Eur Mol Biol Organ) J 17:159-169.
15. Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G, and Coiffier B (2001) Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 113:772-778.
16. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond) 411:494-498.
17. Hopkins KM, Auerbach W, Wang XY, Hande MP, Hang H, Wolgemuth DJ, Joyner AL, and Lieberman HB (2004) Deletion of mouse rad9 causes abnormal cellular responses to DNA damage, genomic instability and embryonic lethality. Mol Cell Biol 24:7235-7248.
18. Jallepalli PV, Lengauer C, Vogelstein B, and Bunz F (2003) The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem 278:20475-20479.
19. Komander D, Kular GS, Bain J, Elliott M, Alessi DR, and Van Aalten DM (2003) Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J 375:255-262.
20. 2/M DNA damage checkpoint. Genes Dev 14:1448-1459.
21. Loegering D, Arlander SJ, Hackbarth J, Vroman BT, Roos-Mattjus P, Hopkins KM, Lieberman HB, Karnitz LM, and Kaufmann SH (2004) Rad9 protects cells from topoisomerase poison-induced cell death. J Biol Chem 279:18641-18647.
22. Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, Heldebrant MP, Vroman BT, Smith BD, Karp JE, et al. (2005) Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 106:318-327.
23. Nabhan C, Krett N, Gandhi V, and Rosen S (2001) Gemcitabine in hematologic malignancies. Curr Opin Oncol 13:514-521.
24. O'Connell MJ and Cimprich KA (2005) G2 damage checkpoints: what is the turn-on? J Cell Sci 118:1-6.
25. Plunkett W, Huang P, Searcy CE, and Gandhi V (1996) Gemcitabine: Preclinical Pharmacology and Mechanisms of Action. Semin Oncol 23:3-15.
26. Roos-Mattjus P, Hopkins KM, Oestreich AJ, Vroman BT, Johnson KL, Naylor S, Lieberman HB, and Karnitz LM (2003) Phosphorylation of human Rad9 is required for genotoxin-activated checkpoint signaling. J Biol Chem 278:24428-24437.
27. Sampath D, Rao VA, and Plunkett W (2003) Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22:9063-9074.
28. Savage DG, Rule SA, Tighe M, Garrett TJ, Oster MW, Lee RT, Ruiz J, Heitjan D, Keohan ML, Flamm M, et al. (2000) Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 11:595-597.
29. Shao RG, Cao CX, and Pommier Y (2004) Abrogation of Chk1-mediated S/G2 checkpoint by UCN-01 enhances ara-C-induced cytotoxicity in human colon cancer cells. Acta Pharmacol Sin 25:756-762.
30. Shi Z, Azuma A, Sampath D, Li YX, Huang P, and Plunkett W (2001) S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 61:1065-1072.
31. Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, Anderson CW, Appella E, Nakanishi M, Suzuki H, et al. (2002) Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO (Eur Mol Biol Organ) J 21:5195-5205.
32. Volkmer E and Karnitz LM (1999) Human homologs of Schizosaccharomyces pombe Rad1, Hus1 and Rad9 form a DNA damage-responsive protein complex. J Biol Chem 274:567-570.
33. Wang H and Hays JB (2002) Mismatch repair in human nuclear extracts. Quantitative analyses of excision of nicked circular mismatched DNA substrates, constructed by a new technique employing synthetic oligonucleotides. J Biol Chem 277:26136-26142.
34. Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, and Grant S (1997) Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-β-D-arabinofuranosylcytosine- induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol 52:1000-1009.
35. Ward IM and Chen J (2001) Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem 276:47759-47762.
36. Waselenko JK, Grever MR, Shinn CA, Flinn IW, and Byrd JC (2001) Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia. Leuk Res 25:435-440.
37. Workman P (2004) Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10:47-51.
38. Zhao H and Piwnica-Worms H (2001) ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 21:4129-4139.
39. Zhao H, Watkins JL, and Piwnica-Worms H (2002) Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 99:14795-14800.
40. Zou L, Cortez D, and Elledge SJ (2002) Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. Genes Dev 16:198-208.